FDA Approves AstraZeneca’s Ultomiris for Neuromyelitis Optica Spectrum Disorder

Action marks the first FDA approval of a long-acting treatment for adult patients with neuromyelitis optica spectrum disorder who are positive for the anti-aquaporin-4 antibody.